PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL

被引：0

作者：

Hillmen, P. ^{[1
]}

Furman, R. R. ^{[2
]}

Coutre, S. E. ^{[3
]}

Sharman, J. P. ^{[4
,5
]}

Pagel, J. M. ^{[6
]}

Barrientos, J. C. ^{[7
]}

Zelenetz, A. D. ^{[8
]}

Kipps, T. J. ^{[9
]}

Flinn, I. ^{[10
]}

Ghia, P. ^{[11
,12
]}

Eradat, H. A. ^{[13
]}

Lamanna, N. ^{[14
]}

Coiffier, B. ^{[15
]}

Pettitt, A. ^{[16
]}

Ye, W. ^{[17
]}

Jahn, T. M. ^{[17
]}

Dubowy, R. ^{[17
]}

O'Brien, S. M. ^{[18
]}

Hallek, M. J. ^{[19
]}

Cheson, B. D. ^{[20
]}

机构：

[1] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

[2] Weill Cornell Med Coll, New York, NY USA

[3] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA

[4] Willamette Valley Canc Inst, Springfield, OR USA

[5] Res Ctr US Oncol Res, Springfield, IL USA

[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[7] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] Ist Sci San Raffaele, Milan, Italy

[13] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[15] Lyon Sud Univ Hosp, Pierre Benite, France

[16] Univ Liverpool, Liverpool L69 3BX, Merseyside, England

[17] Gilead Sci Inc, Foster City, CA 94404 USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] Bonn Univ Hosp Cologne, Cologne, Germany

[20] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P236

引用

页码：55 / 55

页数：1

共 50 条

[41] Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab
Hayslip, John
Fenning, Robert
ONCOLOGIST, 2007, 12 (03): : 338 - 340
[42] Amphotericin-Associated Infusion-Related Reactions: A Narrative Review of Pre-Medications
Scardina, Tonya
Fawcett, Andrea J.
Patel, Sameer J.
CLINICAL THERAPEUTICS, 2021, 43 (10) : 1689 - 1704
[43] CORRELATION OF INFUSION-RELATED REACTIONS (IRR) AND OUTCOME IN PATIENTS RECEIVING NGR-HTNF TREATMENT
Rossoni, G.
Gregorc, V.
Bulotta, A.
Vigano, M. G.
Todisco, G.
Lambiase, A.
Bordignon, C.
ANNALS OF ONCOLOGY, 2012, 23 : 167 - 167
[44] Infusion-related reactions in Black/African American and Hispanic/Latino patients treated with ocrelizumab administered as a shorter infusion
Amjad, F.
Okai, A.
Obeidat, A. Z.
Pei, J.
Acosta, J.
Ndrio, J.
Magrini, F.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 586 - 586
[45] Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT)
Smoot, Kyle
Marginean, Horia
Gervasi-Follmar, Tiffany
Chen, Chiayi
MEDICINA-LITHUANIA, 2024, 60 (04):
[46] Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab
Dawson, Keith
Moran, Mollie
Guindon, Kathleen
Wan, Hui
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (02) : E41 - E48
[47] Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
Park, Keunchil
Sabari, Joshua K.
Haura, Eric B.
Shu, Catherine A.
Spira, Alexander
Salgia, Ravi
Reckamp, Karen L.
Sanborn, Rachel E.
Govindan, Ramaswamy
Bauml, Joshua M.
Curtin, Joshua C.
Xie, John
Roshak, Amy
Lorenzini, Patricia
Millington, Dawn
Thayu, Meena
Knoblauch, Roland E.
Cho, Byoung Chul
LUNG CANCER, 2023, 178 : 166 - 171
[48] Incidence of infusion-related reactions in patients receiving infliximab: Recommendations for administration guidelines
Buch, MH
Lindsay, S
Bryer, D
Fairclough, A
Rees-Evans, B
Emery, P
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 285 - 285
[49] Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?
Sacco, R.
Disanto, G.
Maraffi, I.
Candrian, U.
Kamm, C. P.
Rossi, S.
Schwegler, G.
Gallo, A.
Gobbi, C.
Zecca, C.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 38
[50] Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels
Lujan, Juliana Velez
Lengerke-Diaz, Paula A.
Jacobs, Chaja
Moreno-Cortes, Eider F.
Ramirez-Segura, Cesar A.
Choi, Michael Y.
McCarthy, Colin
Heinen, Alaina
Kipps, Thomas J.
Castro, Januario E.
HAEMATOLOGICA, 2020, 105 (01) : E22 - E25

← 1 2 3 4 5 →